C-Telopeptide Pyridinoline Cross-Links: Sensitive Indicators of Periodontal Tissue Destruction

C-telopeptides and related pyridinoline cross-links of bone Type I collagen are sensitive markers of bone resorption in osteolytic diseases such as osteoporosis and osteoarthritis. We have studied the release of C-telopeptide pyridinoline crosslinks of Type I collagen as measures of bone destruction in periodontal disease. Studies in preclinical animal models and humans have demonstrated the relationship between radiographic bone loss and crevicular fluid C-telopeptide levels. We have recently found that C-telopeptide levels correlate strongly with microbial pathogens associated with periodontitis and around endosseous dental implants. Host-modulation of bone-related collagen breakdown has been shown by studies in humans demonstrating that MMP inhibition blocks tissue destruction and release of C-telopeptides in patients with active periodontal disease.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/72598/1/j.1749-6632.1999.tb07698.x.pd

Marcadores do metabolismo ósseo em gatos

A formação e reabsorção óssea são processos contínuos no organismo e uma das maneiras de avaliar as alterações, a intensidade ou alterações desse processo é pela mensuração dos marcadores do metabolismo ósseo no soro ou na urina. Os objetivos deste estudo foram identificar se os testes comerciais para detectar osteocalcina (OC), peptídeo aminoterminal do procolágeno tipo I (PINP) e telopeptídeo carboxiterminal do colágeno tipo I (ICTP) em seres humanos podem ser utilizados em gatos; e mensurar os valores de OC, PINP e ICTP e correlacioná-los com a densitometria mineral óssea (DMO) em gatos adultos jovens. As médias das concentrações séricas da OC e do ICTP obtidas foram, respectivamente, 0,15±0,03ng mL-1 e 8,59±5,78ng mL-1. A média (±DP) da DMO apresentada foi 1,40±0,23mmAl. Os marcadores do metabolismo ósseo apresentaram baixa correlação entre si e com a DMO. Este estudo concluiu que o teste comercial para mensuração da OC e ICTP em seres humanos podem ser utilizados em gatos, e o teste comercial para mensuração do PINP em seres humano não é viável para essa espécie.Bone formation and resorption are continuous processes and a tool to evaluate alterations these activities is to measure seric or urinary markers of bone metabolism. The aims of this study were to identify if commercial sets available to detect human osteocalcin, (OC) amino-terminal propeptides of procollagen type I (PINP), type-I collagen carboxi-terminal telopeptide (ICTP) are also available for usage in domestic cats; measure seric levels of OC, PINP and ICTP; correlate findings with bone mineral density (BMD) in young adult cats. OC and ICTP means (±SD) was 0.15±0.03ng mL-1 and 8.59±5.78ng mL-1, respectively. BMD while 1.40±0.23mm Al. Bone metabolism markers showed low correlation between then and also BMD. This paper concludes that commercial sets designed for OC and ICTP measures in humans may be used for same purpose in cats to evaluate bone metabolism activity alterations and that kits used for PINP in human should not be used to evaluate in cats

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

Interindividual clinical variability in the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is vast. We report that at least 101 of 987 patients with life-threatening coronavirus disease 2019 (COVID-19) pneumonia had neutralizing immunoglobulin G (IgG) autoantibodies (auto-Abs) against interferon-w (IFN-w) (13 patients), against the 13 types of IFN-a (36), or against both (52) at the onset of critical disease; a few also had auto-Abs against the other three type I IFNs. The auto-Abs neutralize the ability of the corresponding type I IFNs to block SARS-CoV-2 infection in vitro. These auto-Abs were not found in 663 individuals with asymptomatic or mild SARS-CoV-2 infection and were present in only 4 of 1227 healthy individuals. Patients with auto-Abs were aged 25 to 87 years and 95 of the 101 were men. A B cell autoimmune phenocopy of inborn errors of type I IFN immunity accounts for life-threatening COVID-19 pneumonia in at least 2.6% of women and 12.5% of men